Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript
Operator: Good morning and welcome to Harrow's Fourth Quarter and Year-End 2023 Earnings Conference Call. My name is Drew, and I will be your operator for today's call.
Harrow Inc. (HROW)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Opaleye Management James A. Silverman | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.15 | 8,285 | Large Shareholder | 3,795,000 | 2024-04-24 | Filing | |
| $10.29 | 11,715 | Large Shareholder | 3,786,715 | 2024-04-23 | Filing | |
| $10.56 | 29,400 | Large Shareholder | 3,775,000 | 2024-04-19 | Filing | |
| $12.82 | 50,000 | Large Shareholder | 3,745,600 | 2024-03-28 | Filing | |
| $11.59 | 9,000 | Officer, Director | 2,137,525 | 2024-03-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.62 | 40,000 | Director | 26,100 | 2022-09-30 | Filing | |
| $10.04 | 3,900 | Director | 66,100 | 2021-09-24 | Filing | |
| $9.02 | 5,840 | Director | 70,000 | 2021-09-16 | Filing | |
| $9.09 | 14,160 | Director | 75,840 | 2021-09-15 | Filing | |
| $10.75 | 10,000 | Director | 90,000 | 2021-05-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
Harrow (HROW) Fell on Lowering the Guidance
Wasatch Global Investors, an asset management company, released its “Wasatch Micro Cap Value Strategy” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here.
11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in.
Here’s How Harrow (HROW) Weighed on SRK Capital’s Performance
SRK Capital, an investment management firm, released its fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Harrow's Third Quarter 2023 Earnings Conference Call. My name is Betsy, and I will be your operator for today's call.
Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Harrow's Second Quarter 2023 Earnings Conference Call. My name is Kate, and I will be your operator for today's call.
10 Best Small Cap Pharma Stocks to Buy
In this piece, we will take a look at the ten best small cap pharma stocks to buy.
Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Harrow's First Quarter 2023 Earnings Conference Call. My name is Joe, and I will be your operator for today's call.
Harrow Health, Inc. (NASDAQ:HROW) Q4 2022 Earnings Call Transcript
Operator: Good afternoon. And welcome to Harrow's Q4 2022 Earnings Conference Call. My name is MJ, and I will be your operator for today's call.
Is Harrow Health (HROW) an Undervalued Stock?
SRK Capital, an investment management company, recently released its fourth-quarter investor letter. A copy of the same can be downloaded here.
Billionaire Hedge Funds
